
Electronic Theses and Dissertations, 2004-2019

2012

Amelioration Of Amyloid Burden In Advanced Human And Mouse Alzheimer's Disease Brains By Oral Delivery Of Myelin Basic Protein Bioencapsulated In Plant Cells

Neha Kohli
University of Central Florida



Part of the [Biotechnology Commons](#), and the [Molecular Biology Commons](#)

Find similar works at: <https://stars.library.ucf.edu/etd>

University of Central Florida Libraries <http://library.ucf.edu>

This Masters Thesis (Open Access) is brought to you for free and open access by STARS. It has been accepted for inclusion in Electronic Theses and Dissertations, 2004-2019 by an authorized administrator of STARS. For more information, please contact STARS@ucf.edu.

STARS Citation

Kohli, Neha, "Amelioration Of Amyloid Burden In Advanced Human And Mouse Alzheimer's Disease Brains By Oral Delivery Of Myelin Basic Protein Bioencapsulated In Plant Cells" (2012). *Electronic Theses and Dissertations, 2004-2019*. 2379.

<https://stars.library.ucf.edu/etd/2379>

AMELIORATION OF AMYLOID BURDEN IN ADVANCED HUMAN AND
MOUSE ALZHEIMER'S DISEASE BRAINS BY ORAL DELIVERY OF
MYELIN BASIC PROTEIN BIOENCAPSULATED IN PLANT CELLS

by

NEHA KOHLI

B.S. State University of New York at Binghamton, NY, 2010

A thesis submitted in partial fulfillment of the requirements
for the degree of Master of Science
in the Burnett School of Biomedical Sciences
in the College of Medicine
at the University of Central Florida
Orlando, Florida

Fall Term
2012

Major Professor: Henry Daniell

© 2012 Neha Kohli

ABSTRACT

One of the pathological hallmarks of Alzheimer's disease (AD) is the amyloid plaque deposition in aging brains by aggregation of amyloid- β (A β) peptides. In this study, the effect of chloroplast derived myelin basic protein (MBP) fused with cholera toxin subunit B (CTB) was investigated in advanced diseased stage of human and mouse AD brains. The CTB-fusion protein in chloroplasts facilitates transmucosal delivery in the gut by the natural binding ability of CTB pentameric form with GM1 receptors on the intestinal epithelium. Further, bioencapsulation of the MBP within plant cells confers protection from enzymes and acids in the digestive system. Here, 12-14 months old triple transgenic AD mice were fed with CTB-MBP bioencapsulated in the plant cells for 3 months. A reduction of 67.3% and 33.3% amyloid levels in hippocampal and cortical regions, respectively were observed by immunostaining of brain sections with anti- A β antibody. Similarly, 70% decrease in plaque number and 40% reduction of plaque intensity was observed through thioflavin S (ThS) staining that specifically stains amyloid in the AD brain. Furthermore, *ex vivo* 3xTg AD mice brain sections showed up to 45% reduction of ThS stained amyloid levels when incubated with enriched CTB-MBP in a concentration dependent manner. Similarly, incubation of enriched CTB-MBP with *ex vivo* postmortem human brain tissue sections with advanced stage of AD resulted up to 47% decrease of ThS stained amyloid plaque intensity. Lastly, lyophilization of plant material facilitates dehydration and long term storage of capsules at room temperature, in addition to increasing CTB-MBP concentration by 17 fold. These observations offer a low cost solution for treatment of even advanced stages of the AD by facilitating delivery of therapeutic proteins to central nervous system to address other neurodegenerative disease.

This thesis is lovingly dedicated to my mother, Reena Kohli, M.S. Her support, encouragement, and constant love have upheld me all through my life.

ACKNOWLEDGMENTS

I am grateful to my committee chair, Dr. Daniell for his exquisite consideration to detail and for his demand for excellence. I would thank him for the opportunity he provided me to work as an emerging researcher in his lab and providing his intellectual advice. I am obliged to the members of my committee Dr. Kim and Dr. Cheng for their time, encouragement and offering intellectual expertise. I would like to thank Dr. Chan for providing the brain tissue samples in this project. I would also like to thank Donevan Westerveld for his help and support to carry forward this project.

TABLE OF CONTENTS

LIST OF FIGURES	viii
LIST OF ACRONYMS/ABBREVIATIONS	ix
CHAPTER ONE: INTRODUCTION.....	1
Alzheimer’s Disease.....	1
Myelin Basic Protein.....	2
Blood Brain Barrier.....	3
Plant Derived Therapeutic Proteins.....	3
Chloroplast Transformation	4
Bioencapsulation and Oral Delivery of Proteins.....	5
CHAPTER TWO: MATERIALS AND METHODS	7
Southern Blot Analysis.....	7
Plant genomic DNA Extraction and Restriction Digestion	7
Agarose gel Electrophoresis and Transfer of DNA to Membrane	7
Hybridization and Autoradiography	8
Confirmation of Inheritance	8
Protein Extraction and Bradford Assay.....	8
Western Blot Analysis.....	9
Densitometric Studies for Quantification of Protein.....	10

Lyophilization	11
CTB GM1 Assay.....	11
<i>Ex Vivo</i> Studies.....	12
Animal Studies	13
Oral delivery of 3xTgAD Mice with Bioencapsulated CTB-MBP	13
Immunohistochemistry and Thioflavin S Staining	13
CHAPTER THREE: RESULTS	15
Confirmaion of transgene integration and characterization of CTB-MBP protein expressed in chloroplasts.....	15
Reduction of amyloid levels in 3xTgAD mice brains by CTB-MBP incubation	19
Reduction of amyloid levels in post-mortem human AD brains by CTB-MBP	22
Reduction of Amyloid Levels in 3xTgAD mice upon oral delivery of bioencapsulated CTB-MBP	25
CHAPTER FOUR: DISCUSSION.....	29
REFERENCES	34

LIST OF FIGURES

Figure 1: Confirmation of homoplasmy and CTB-MBP protein expression in transplastomic tobacco	18
Figure 2 : Reduction of amyloid plaque load in <i>ex vivo</i> mouse brain tissue sections incubated with the CTB-MBP chloroplast expressed protein.	21
Figure 3: Reduction of amyloid plaque in <i>ex vivo</i> post-mortem AD brain tissue sections incubated with the CTB-MBP chloroplast expressed protein	24
Figure 4: Oral delivery of CTB-MBP chloroplast expressed protein diminished the amyloid plaque burden in a mouse model of AD.	28

LIST OF ACRONYMS/ABBREVIATIONS

aadA – Aminoglycoside 3' Adenyltransferase

AD – Alzheimer's Disease

BBB- Blood Brain Barrier

BSA –Bovine Serum Albumin

CTB - Cholera Toxin Beta Subunit

CTB-MBP – Cholera Toxin Beta Subunit fused with Myelin Basic Protein

DNA - Deoxyribonucleic Acid

dNTP - Deoxy Nucleotide Triphosphate

DTT - Dithiothreitol

EDTA - Ethylenediaminetetraacetic Acid

ELISA - Enzyme Linked Immunosorbent Assay

GM1 - Monosialotetrahexosylganglioside

HCl -Hydrochloric acid

H₂SO₄ - Sulfuric acid

Kb - Kilobase

kDa – Kilodalton

MBP – Myelin Basic Protein

MgCl₂ - Magnesium chloride

MS - Murashige and Skoog

NAA - Naphthalene Acetic Acid

NaCl - Sodium chloride

NaOH - Sodium hydroxide

PBS - Phosphate Buffered Saline

PBST- Phosphate Buffered Saline-Tween 20

PCR - Polymerase Chain Reaction

PMSF -Phenylmethanesulfonylflouride

³²P - Radioactive phosphorus

psbA - Photosystem b/A

RMOP - Regeneration Media of Plants

RNA - Ribonucleic Acid

SDS-PAGE - Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis

SSC - Sodium Chloride and Sodium Citrate solution

TEMED - Tetramethylethylenediamine

WT - Untransformed Plant

UTR - Untranslated Region

UV - Ultraviolet

CHAPTER ONE: INTRODUCTION

Alzheimer's Disease

Alzheimer's disease (AD), the most prominent form of dementia, has been estimated to affect 36 million people globally in World's Alzheimer Report (WAR) 2010 (1), with a projected increase of up to 115 million at an annual cost of \$604 billion. The 2011 WAR report concludes that up to 28 million people with dementia, lack efficient diagnosis, treatment and care (2), increasing the "treatment gap" from high to low and middle income countries. Many potential therapies for inhibiting cognitive AD symptoms are in development including inhibitors to cholinesterase (3), memantine (4), and other drugs to reduce AD burden. Accumulation of beta-amyloid ($A\beta$) plaques, attrition of neurons and synapses, rapid clearance of $A\beta$ and neurofibrillary tangles (NFT's) formation (5, 6) are major challenges in treatment of AD. Biomarkers can play an important role in therapeutic treatments by detecting the pathology and biological effects on cerebral amyloid clearance followed by other downstream processes. Early detection of AD by identification and quantification of *in vivo* beta-amyloid through ligands specific to amyloid is a significant advancement. Amyloid imaging has progressed through positron emission tomography (PET) using Pittsburgh compound B as an amyloid ligand (7, 8). Along with magnetic resonance imaging (MRI) that correlates neuro-psychological decline in AD patients (8), other biomarkers facilitate intervention of AD in a large number of patients at preclinical stages and clinical trials. The cleavage of amyloid precursor protein (APP) produces $A\beta_{40}$, $A\beta_{38}$, $A\beta_{42}$ and $A\beta_{46}$ (9), among which $A\beta_{42}$ aggregates to form extracellular plaques. The increase in plaque volume leads to loss in synaptic function and neuronal degeneration (10). Active and passive immunotherapy involves administration of amyloid peptides and anti-

amyloid antibodies respectively to evoke an immune response. Reduction in A β levels have been reported in animal models through active and passive immunotherapies (11, 12). However phase II clinical trial of the AN1792 A β vaccine was discontinued due to side effects and meningo-encephalitis observed in ~6% of the immunized AD patients (11, 12). Other medications like donepezil or acetylcholinesterase offer only suggestive benefits rather than preventing progression of the disease (13, 14); hence strategies to clear pathologic proteins as the potential targets for AD are needed.

Myelin Basic Protein

Based on insights from AD pathogenesis, several therapeutic approaches are developed to reduce amyloid burden. Liao *et al.* (15) showed the strong interaction of myelin basic protein (MBP) with A β peptides, thereby preventing their assembly into mature amyloid fibrils. The “classic” isoform of MBP, 18.5kDa besides seizing the cytoplasmic leaflets of myelin membranes in myelin sheath (16), holds serine proteinase and autocatalytic activity. Moreover, it accounts for 30% of total myelin protein and represents a major structural component of myelin sheaths in the central nervous system. Interaction of MBP with A β peptides and their prevention into amyloid fibrils has been shown (17). Furthermore, degrading activity of MBP was demonstrated by incubation with brain sections of A β precursor protein transgenic mice *in situ* (15) by binding to A β at a site located in the N-terminal domain of MBP. Moreover it has shown to play an important role in amyloid cytotoxic effects in cortical neurons (18). The effect of MBP by delivering it *in vivo* into the brain can be hypothesized to reduce the amyloid plaques as well.

Blood Brain Barrier

To ensure the regulation of transport of substances inside and outside the brain, complex and tight intracellular junctions guard the blood brain barrier (BBB). This regulation further limits the passage of lipophilic molecules, proteins, metabolites across BBB (19). Moreover, the delivery of drugs intravenously does not offer an advantage for neurodegenerative diseases because of the prevention of an optimal uptake across BBB. Recently, studies have shown that polymeric nanoparticles coated with GM1 binding peptide promoted transcytosis as an important process for BBB penetration (20, 21). Further, receptor mediated endocytosis (RMT) and internalization is triggered through involvement of caveolae, which is enriched in ganglioside GM1 (21, 22). Selection of high affinity GM1 binding ligands, like pentavalent CTB address the process of transcytosis across BBB remarkably. Studies have also shown that CTB can bind to GM1 on the surface of neurons and enter through endocytosis (23). The fusion of CTB with therapeutic proteins can offer an optimal delivery system to transport the protein across BBB, *in vivo*. Similarly, MBP fused with CTB was hypothesized to cross through receptor mediated delivery BBB *in vivo* in mice and degrade A β aggregates.

Plant Derived Therapeutic Proteins

To address expensive fermentation systems, molecular farming has been developed as an alternative new technology for the production of therapeutic proteins. Recently, FDA approved a carrot cell based system for production of the first human therapeutic protein (24). Expensive chemical synthesis and purification, delivery using injections, and process of cold storage can be eliminated by low cost production of recombinant proteins in plants. The two major processes

for the derivation of proteins from plants include nuclear and plastid derived transformation. Plants provide an excellent bioreactor to produce proteins at a low cost and provide antigen protection by bioencapsulation. Lyophilization process of plant material helps to package capsules in a particular dosage or size, eliminates microbes and allows keeping plant material at room temperature for several months without disrupting its functionality (25).

Chloroplast Transformation

Many advantages are offered by chloroplast transformation and genetic engineering. As each plant cell contains 100 chloroplast organelles and each chloroplast contains up to 100 chloroplast genome; there exists 10,000 copies of chloroplast genome in each plant cells. This phenomenal copy number helps to achieve high expression of transgene levels by chloroplast genetic engineering. Up to 72% total leaf protein (26) has been reported for biopharmaceutical proteins in transgenic chloroplasts. Unlike nuclear transformation, chloroplast genome is not transferred through pollen, offering gene containment through maternal inheritance (27). Through site specific homologous recombination in chloroplast genome, positional effect or gene silencing are prevented. In addition, not only chloroplasts can transcribe polycistronic mRNA of plastids providing efficient expression of multiple genes, but also process posttranslational modifications of eukaryotic protein (28). Many genetically engineered plants for expression of proinsulin (29), insulin and C peptide (30), exendin 4 (25) for treatment of diabetes or blood clotting factor IX for hemophilia B (31), bacterial antigens like anthrax protective antigen (32), viral antigens like human papilloma virus L1 (33), dual vaccine to against cholera and malaria (34) have been expressed ideally in chloroplast system. Moreover, *Nicotiana tabacum*

chloroplasts have served as a bioreactor for its ability to maintain high biomass, and transformation efficiency. Likewise, edible crop including lettuce are used for transformation not only because it decreases the production cost but also offer ideal system for oral delivery of therapeutic proteins. In a similar fashion, generation of transgenic plants for MBP expression through chloroplast transformation was carried out in this study.

Bioencapsulation and Oral Delivery of Proteins

Oral delivery can be facilitated by bioencapsulation of foreign protein expressed in plant cells. These cells are ensured protection in the stomach from acids and enzymes. As they meet microbes in the gut, plant cell proteins are released in circulatory system. Further, lyophilization of plant cells allows preparation of capsules and long term storage of vaccines at room temperature, eliminating microbes, cold storage, purification and injections. Oral delivery of biopharmaceutical proteins and vaccines efficiently across intestinal mucus membrane is facilitated by GM1 receptors on the intestinal epithelial cells by binding to the CTB half of the fusion protein. Five B subunits monomers in the cholera toxin (CT) are assembled into a pentameric ring structure, which binds specifically to oligosaccharide domain of GM1 receptor (35). Hence, CTB subunit fused to a protein ensures protein delivery to the immune or circulatory system through a receptor mediated mechanism. Moreover, this study focuses on the delivery of CTB fusion protein to the brain. To test the delivery of therapeutic protein, MBP across BBB, MBP was fused with CTB. The GM1 receptors of the brain (36) are anticipated to cross link with CTB portion of the fusion protein and act as a vehicle to deliver MBP across

BBB. The concept of bioencapsulation will allow the protein to remain stable and actively perform its activity of degrading amyloid beta in Alzheimer's disease brain.

CHAPTER TWO: MATERIALS AND METHODS

Southern Blot Analysis

Plant genomic DNA Extraction and Restriction Digestion

Total genomic DNA from untransformed wild type and transplastomic lines was extracted using DNeasy plant mini kit protocol (Qiagen). Extracted genomic DNA was quantitated using Nanodrop (Biorad), then three micrograms of DNA was digested with Afl III enzyme. The reaction mixture contained 4 μ l of 10X buffer (New England Biolabs), 3 μ g of plant genomic DNA, 1 μ l of enzyme for a final volume adjusted to 40 μ l with distilled water. The digestion reaction was incubated at 37°C overnight.

Agarose gel Electrophoresis and Transfer of DNA to Membrane

The digestion of DNA samples was confirmed by running them on a 0.8% agarose gel at 60V. The gel was then rinsed twice with distilled water for 5 min each to facilitate efficient transfer. To facilitate the binding of radio-labeled probe to the corresponding genomic DNA fragment, AflIII digested DNA was denatured by soaking the gel in transfer buffer (0.4N NaOH, 1M NaCl) for 20 min. The separated digested genomic DNA in the gel were transferred overnight by placing it facing the presoaked nylon membrane followed by filter paper and gentle pressure by stack of paper towels. Weights were placed on top for balance optimal contact between gel and membrane. Following day, membrane was rinsed with 2X SSC (3M NaCl, 0.3M sodium citrate) 2 times for 5 min each. Membrane was dried on a filter paper and was cross linked using GS gene linker UV chamber at C3 setting.

Hybridization and Autoradiography

After overnight transfer, membrane was prehybridized with 10 ml of QuickHyb prehybridization solution (Stratgene) at 68°C for 1 hr on a rotary chamber. In the meantime 5-10µl of the flanking probe was added to 100 µl of salmon sperm DNA, vortexed and heated at 94°C for 5 min. Next, the probe mixture was added to hybridization bottle containing the prehybridized membrane and incubated for 1 hr at 68°C. Following incubation, the membrane was washed twice with 25ml of wash buffer 1 (2 X SSC & 0.1% SDS) at room temperature for 15 min each and washed twice with 25ml of wash buffer 2 (0.1X SSC and 0.1% SDS) at 60°C for 15 min each. The membrane was wrapped in a saran wrap and radioactivity was checked using a Geiger counter. X-ray film was exposed to the hybridized membrane in dark and kept at -80°C for 12-72 hr depending on the radioactive count. The exposed X-ray film was developed in a film processor.

Confirmation of Inheritance

The plants that were positive from southern blot analysis were multiplied and transferred to Jiffy pots (Harris Seeds). After acclimatization in an incubation chamber for about 2 weeks, plants were transferred to greenhouse for biomass. Seeds from self pollinated transplastomic plants were collected and germinated in ½ MS media containing 2% (w/v) sucrose and spectinomycin (500mg/L) along with wild type seeds in culture room to check for inheritance.

Protein Extraction and Bradford Assay

Expression level of CTB fused MBP protein was examined at different time of harvest and developmental stages. The total leaf proteins of transplastomic plants grown in greenhouse

were extracted according to leaf ages such as young, mature and old at different time points - 10am, 2pm, and 6pm. The leaf material frozen in liquid nitrogen was then grinded to fine powder using motor and pestle. In 300µl of plant extraction buffer (100 mM NaCl, 10 mM EDTA, 200mM tris HCl pH 8.0, 0.05% Tween-20, 0.1% SDS, 14 mM βME, 200 mM sucrose, 2 mM PMSF, 1X protease inhibitor cocktail) 100mg of finely grinded transplastomic leaf was added. The total leaf protein was homogenized by mixing for 10 minutes at 4°C, followed by centrifugation at 14,000 rpm for 5 min to obtain the supernatant and pellet fractions. The pellet was discarded and supernatant was used for quantification. The concentration of the total leaf protein was determined using the Bio-Rad protein assay dye reagent. The standard curve was plotted by serial diluting 0.8µg/µl BSA down to 0.05mg/ml. The supernatants were diluted with water in a ratio of 1:10, 1:20 and 1:40. A 96 well assay plate was used to which 10µl of each sample and BSA standard was added in duplicates. Bradford dye reagent (200µl) was added to each well and absorbance was measured at 595 nm using a plate reader.

Western Blot Analysis

To check for expression of CTB-MBP fusion protein, western blot analysis was performed. The samples were diluted with 2X sample loading buffer (3.55 ml dH₂O, 1.25 ml 0.5M Tris-HCl pH 6.8, 2.5 ml glycerol, 2 ml 10% SDS, 0.2 ml 0.5% bromophenol blue), boiled for 10 minutes, centrifuged, loaded on 12% SDS-PAGE gel and ran at 110 V. The proteins were separated according to their molecular weights. Next, the proteins were transferred to a nitrocellulose membrane using Bio-Rad electro blotting transfer apparatus at 85 V for 1 hr. Membrane was then incubated in PTM (PBST with 3.5% dry milk) at room temperature for 1 hr

with gentle shake to block non-specific binding. CTB-MBP protein was detected using anti-CTB rabbit primary polyclonal antibody (Sigma) diluted in PTM (1:12000). The fusion protein was also probed with rabbit anti-human MBP primary monoclonal antibody (1:1000, Abcam). The membrane was incubated with respective primary antibodies overnight at 4°C with gentle shaking. Following day, the membrane was washed twice with PBS-T for 5 min each at room temperature. Next, goat anti-rabbit IgG conjugated to horse radish peroxidase (HRP) secondary antibody diluted in PTM (1:4000) was added to the membrane and incubated at room temperature for 1.5 hr with gentle shaking. Next, membrane was washed thrice with PBS-T for 10 min each followed by a last wash with PBS for 15 min. Supersignal West Pico chemiluminescent substrate (Thermo Scientific) was added to the membrane and a chemiluminescent signal was detected on autoradiography film through an automated X-ray film processor. Similarly native PAGE was carried out with detection of fusion protein in native state as mentioned above, except that DTT and SDS were removed during preparation of gels, sample buffer and plant extraction buffer and the samples were not boiled.

Densitometric Studies for Quantification of Protein

For quantification of the CTB-MBP protein, developed X-ray film against immunoblotted membrane probed with anti-CTB antibody was used for densitometric analysis. To plot the standard curve for CTB protein, known amounts of CTB (50, 100, and 150 ng) were loaded for immunoblot analysis. The concentration of CTB-MBP expressed in transplastomic plants was determined by plotting the detected bands onto the standard curve using the

Alphaimager and Alpha ease FC software. The total soluble protein % was also calculated using formula described before (37).

Lyophilization

CTB-MBP frozen material was lyophilized to obtain higher protein concentration by freeze drying the material using Freezone Benchtop Freeze Dry Systems (Labconco) in vacuum for 48 hrs at -50°C and 0.036mBar. Following lyophilization, freeze dried leaf material was grinded using coffee blender (Hamilton Beach) for 2 min at maximum speed (pulse on for 10 sec and off for 10 sec) then stored under moisture-free condition stored at room temperature. To check the stability and functionality of the lyophilized protein, proteins were extracted described above then immunoblot with anti-CTB antibody was conducted and compare its protein expression to that of fresh weight leaf material.

CTB GM1 Assay

To investigate the proper formation of pentameric structure of CTB-MBP fusion protein, GM1 (monosialotetrahexosylganglioside) assay was done with soluble proteins extracted from the CTB-MBP expressing fresh weight and lyophilized leaf material, and purified CTB. GM1 ganglioside (Sigma G-7461) was coated by incubating 100 μl of GM1 (3 $\mu\text{g}/\text{ml}$) in bicarbonate buffer, (15 mM Na_2CO_3 , 35 mM NaHCO_3 , pH 9.6) at 4°C overnight. PTM (100 μl) was coated as a control. Plate was washed three times with PBST and distilled water. PTM (200 μl) was added and incubated for 2 hrs at 37°C for blocking non specific binding. The plate was again washed three times with PBST and water. Various concentrations of protein extracted from transplatomic

and untransformed plants diluted in plant extraction buffer were added to the wells and incubated overnight at 4°C, including CTB protein as control. Following day, the plate was washed thrice with PBST and water, and incubated with 1:12,000 dilution of rabbit anti-CTB primary antibody (Sigma) for 1 hr at 37°C. Following set of washings for three times with PBST and water, the plate was incubated with 1:4000 dilution of anti-rabbit IgG secondary antibody conjugated to horse radish peroxidase (Southern biotech, USA) for 1 hr at 37°C. The plate was washed three times with PBST and water. Then 100µl of TMB (Signal Transduction Products) was added and kept in dark for 20-30 min depending on the color reaction. The reaction was stopped by adding 50µl of 2N H₂SO₄. Absorbance was measured at 450 nm by using a microplate reader.

Ex Vivo Studies

Ex vivo brains from 24 months old 3xTg AD mice were received from National Institute of Aging (NIA), for which 7µm cryostat sections were collected on slides. Seven adjacent sections were incubated with 25µg or 50µg of 33% purified CTB-MBP plant protein in PBS. Commercial CTB alone, BSA and untransformed plant protein were also used for concentration-dependent incubation as controls simultaneously. After 2 days of incubation at 37°C, sections were stained with Thioflavin S (ThS, Sigma), imaged and quantified using NIS Elements for Advanced research software using Nikon Eclipse TE2000-E fluorescence microscope. Threshold intensity was based on the intensity of background staining in control sections. The selected threshold was held constant across all experimental sections. *Ex vivo* post mortem brain tissues from Alzheimer's disease patients, processed and received as described before (38) were deparaffinized and rehydrated to ensure good staining of the tissue. The slides were passed

through xylene followed by graded washes with xylene and ethanol, with a final wash of molecular grade water. Brain sections were incubated with 50 μ g of CTB-MBP (33% purity) transplastomic plant or untransformed plant material. After 2 days of incubation at 37°C, sections were stained with ThS and DAPI to acquire images as described above.

Animal Studies

Oral delivery of 3xTgAD Mice with Bioencapsulated CTB-MBP

The 3xTg AD mice were received from NIA. These mice were derived by microinjecting two independent transgenes encoding human APP (Sweden) and tau (P301L) into single embryos harvested from the homozygous mutant PS1 (M146V) knockin (PSI-KI) mice, as described previously (72). For these studies, 12-14 months old (at the start of study) 3xTg AD mice were used for oral delivery of CTB-MBP. Animals, housed under pathogen free conditions, were treated under Institutional Animal Care and Use Committee-approved protocols. The lyophilized leaf material for oral dose (31.2 μ g/300 μ l/day) of either transgenic (n=10) or NT (n=4) was delivered three times a week for three months. A set of mice (n=4) were kept unfed. For the oral delivery experiments, the lyophilized material was prepared by adding 4mL of PBS to 500mg of lyophilized and powdered CTB-MBP expressing plant material on ice right before the oral gavage.

Immunohistochemistry and Thioflavin S Staining

On the day of sacrifice, all mice were perfused with saline following which the brains were removed. One hemisphere of the brain tissue from 3xTg AD mice was prepared for histological analysis in 4% paraformaldehyde overnight whereas the three brain regions-

cerebellum, hippocampus, and cortex were dissected from the other hemisphere for A β measurements. Brain cryosections (8 μ m thick) from the coronally mounted other hemisphere of 3xTgAD mice delivered orally with the powdered lyophilized CTB-MBP expressing transplacental plants was obtained on slides using microtome slicing system (Fischer). Adjacent five sections were exposed for 1 hr to PBS containing 0.1% Triton X-100 (Sigma) and 5% normal goat serum (Invitrogen, Camarillo, CA) to block nonspecific antibody binding, followed by incubation overnight with primary antibody, polyclonal anti-amyloid beta (1:200 Cell Signaling # 2454), overnight at 4°C. To test for nonspecific staining by the secondary antibodies, additional slides were processed in a similar fashion with the primary antibodies excluded. All slides were then rinsed for 1 hr at room temperature in several changes of PBS and incubated in the dark for 1 hr at RT in PBS that contained 5% NGS and the fluorescent secondary antibody, Alexa Fluor 568-conjugated IgG (1:200). Following incubation with secondary antibody, the cryosections were counterstained with Hoescht 33342 (Invitrogen), images were acquired by Nikon Eclipse TE2000-E fluorescence microscope. These images were then processed by NIS Elements for Advanced Research, with the input levels adjusted to span the range of acquired signal intensities exactly. Statistical analysis for the data was analyzed by single factor ANOVA. Similarly, following PBS rehydration, adjacent five sections were stained with 0.02% ThS in 70% EtOH for 8 minutes. This was followed by rinsing the slides in 50-80% EtOH and distilled water respectively and cover slipped with DAPI solution for acquiring images as mentioned before.

CHAPTER THREE: RESULTS

Confirmation of transgene integration and characterization of CTB-MBP protein expressed in chloroplasts

Transplastomic chloroplast lines were confirmed by Southern blots confirming site specific integration of transgene into the spacer region between *trnI* and *trnA* genes. Digestion of untransformed (WT) plant DNA with *AflIII* showed 4.2kb fragment after hybridizing with ³²P-labeled *trnI-trnA* flanking probe and transplastomic CTB-MBP lines showed only the 6.7kb fragment, confirming homoplasmy through site specific integration of transgene (Fig. 1a). Evaluation of foreign gene expression at different developmental stages - young(Y), mature (M) and old (O) and at time of harvest – 10am, 2pm, 6pm, showed the highest MBP expression in mature leaves at 6pm (Fig. 1b and 1c). Enhanced translation of gene in the light by *psbA* promoter and 5'UTR regions located upstream of MBP gene cassette should contribute to maximal expression observed later in the evening. Immunoblots probed with CTB (Fig. 1d) and MBP (Fig. 1e) antibody showed ~28.5kDa fusion protein monomer in CTB-MBP transplastomic lines. Fresh weight leaves expressed up to 2% of total leaf protein, where a 17 fold enhanced concentration of the protein was achieved by lyophilization of the plant material (Fig. 1f and j). Equal loading of protein showed a significant difference in accumulation of CTB-MBP between fresh and lyophilized materials (Fig. 1f). Moreover immunoblots probed with CTB antibody showed that lyophilized material maintained stability at room temperature and protection from degradation over 7 months of duration (Fig. 1g). The functionality of CTB-MBP fusion protein was evaluated by GM1 ELISA, where the ability of CTB to bind to the GM1 receptors depends on its pentameric form. GM1 binding assay showed that pentamers of fresh weight and

lyophilized CTB-MBP were formed; this confirms proper folding and formation of disulfide bonds (Fig. 1i). Non-reducing native PAGE immunoblots probed with CTB antibody further confirmed the native pentameric formation (Fig. 1h) within transgenic chloroplasts, attesting functionality of CTB-MBP for further *in vivo* and *in vitro* studies. Lyophilization process preserved the folding and disulfide bonds of CTB-MBP protein even after prolonged storage (Fig. 1j).














Figure 1: Confirmation of homoplasmy and CTB-MBP protein expression in transplastomic tobacco

(a) Digestion with AflIII yields 4.2kb and 6.7kb fragments in WT and transplastomic lines respectively as shown in southern blot analysis. (b, c) Protein analysis showing CTB-MBP protein expression relative to leaf's age and time of harvest. (d, e) Western analysis of CTB-MBP expression in fresh (F) and lyophilized (L) transgenic plant extracts. SDS-PAGE with anti-CTB antibody (d), Lane 2, 3, 4 - 12.5ng, 25ng, 37.5ng purified CTB standard respectively; lane 5 & 6 - 20ug of F and L respectively. SDS-PAGE with anti-MBP antibody (e), Lane 2 & 3 - 20ug of F and L respectively. (f) SDS PAGE with anti-CTB antibody for normalization of F and L transgenic plant protein. Equal quantity (100mg) of F and L samples that were obtained by adding equal volume of plant extraction buffer (300uL). (g) Western analysis showing long term stability of CTB-MBP (L) after storage at room temperature for seven months. Lane 1, 2, 4, 5, 7 - 20ug of L in stored at different months, lane 8 - 12.5ng CTB standard. (h) Native PAGE with anti-CTB antibody. Lane 1- 37.5ng purified CTB standard; lane 2 & 3 - 2ug of F and L respectively. (i) GM1 ELISA assay for functional pentamers of purified CTB (25ng), transgenic CTB-MBP protein in 20ug of F, L and WT extracts. (j) Quantification of CTB-MBP protein (mg of protein/g of total leaf) in F and L plant extracts.

Reduction of amyloid levels in 3xTgAD mice brains by CTB-MBP incubation

Ex vivo studies of thioflavin S (ThS) stained brain sections (Fig. 2a) from 24 months old 3xTg AD mice showed reduction in amyloid plaques in a concentration-dependent manner when incubated with chloroplast-derived CTB-MBP. ThS fluorescence reduction from 44-60% was detected with 2 days incubation with 33% purified 25-50ug of CTB-MBP plant derived protein in adjacent brain sections (Fig. 2b). Control incubations with protein extract from untransformed plants, PBS buffer or purified CTB (commercial source) under identical conditions didn't show any decrease in ThS intensity. The decreased intensity in CTB-MBP incubated sections as compared to WT treated or other controls, shows that CTB-MBP at an optimal concentration of 50 μ g is able to break and/or remove the amyloid fragments, thereby reducing their thioflavin S fluorescence. Data shown is mean \pm S.D of values obtained from seven adjacent sections and evaluated from a total of 63 fluorescence images.

a



b






Figure 2 : Reduction of amyloid plaque load in *ex vivo* mouse brain tissue sections incubated with the CTB-MBP chloroplast expressed protein.

(a) Sagittal serial sections of brains from 3xTg AD mice were incubated with 25 and 50 μ g recombinant CTB-MBP protein partially purified from transgenic leaf extracts or 25 or 50 μ g commercially available purified CTB for 2 days and then stained with 0.02% ThS solution to visualize the central dense core of compact amyloid (green) and with DAPI to identify cell nuclei (blue) by fluorescence microscopy. As controls, adjacent sections were incubated with 25 or 50 μ g of untransformed leaf extracts or saline alone and processed for ThS staining in parallel. Shown are sections including the hippocampus and cortex of representative 24 -month-old 3xTg AD mice. (Scale bar: 10 μ m). (b) Quantification of the relative amounts of amyloid plaque load in the ThS stained sections after incubation with the indicated proteins or saline alone as described in (a). The mean plaque counts in the DG, CA1 and CA3 hippocampal and cortical regions per section (in cortex, mantle and pallium regions) were determined with NIS Elements for Advanced Research. Data shown is mean \pm S.D of values obtained from seven adjacent sections and two fields per section.

Reduction of amyloid levels in post-mortem human AD brains by CTB-MBP

Ex vivo studies of ThS stained brain sections of post mortem brain tissues from Alzheimer's disease patients (Fig. 3a) were conducted with incubation of CTB-MBP chloroplast expressed protein. An optimal working concentration of 50µg of 33% purified CTB-MBP protein was obtained from *ex vivo* mice studies. Next, adjacent brain sections stained with ThS upon 2 days of incubation with 33% purified 50µg of CTB-MBP, showed 47.5% ThioS fluorescence reduction of stained amyloid plaques (Fig. 3B). As observed in *ex vivo* mice brain sections, the decreased intensity in CTB-MBP incubated human sections when compared to untransformed plant extract shows that MBP through its serine proteinase activity was also able to break down plaques and/or remove the smaller amyloid fragments, thereby reducing their ThS fluorescence in human tissue as well. Data shown is mean \pm S.D of values obtained from sections of five AD patients and evaluated from a total of 10 fluorescence images.

a



b










Figure 3: Reduction of amyloid plaque in *ex vivo* post-mortem AD brain tissue sections incubated with the CTB-MBP chloroplast expressed protein


Sections of the parietal cortex from AD patients (a) were incubated with 50µg recombinant CTB-MBP protein partially purified from transgenic leaf extracts or 50µg of partially purified untransformed leaf material for 2 days and then stained with 0.02% Thioflavin S solution to visualize the central dense core of compact amyloid (green) and with DAPI to identify cell nuclei (blue) by fluorescence microscopy. As controls, adjacent sections were incubated with 50µg of untransformed wild-type leaf extracts or saline alone and processed for ThS staining in parallel. (Scale bar: 10µm). (b) Quantification of the relative amounts of amyloid plaque load in the Thio-S stained sections after incubation with the indicated proteins or saline alone as described in (a). The mean plaque counts per section were determined with NIS Elements for Advanced Research. Data shown is mean \pm S.D of values obtained from sections of five AD patients and two fields per section.

Reduction of Amyloid Levels in 3xTgAD mice upon oral delivery of bioencapsulated CTB-MBP

The effect of oral delivery for a period of three months with either bioencapsulated CTB-MBP (31.2ug/day), untransformed WT plant cells or unfed mice was evaluated in brain sections of 3xTgAD mice, that were 12-14 months old at the start of this study. Stained adjacent cortex and hippocampus sections of control and CTB-MBP treated mice stained with the anti- β -amyloid antibody (Fig. 4a, red) or ThS (Fig. 4b, green) were examined and quantified as described in methods. Most plaques were found in the hippocampus region, particularly DG, CA1 and CA3 sites, from where they started diffusing to the cortex as the age of mice progresses. $A\beta$ level reduction of up to 67.3% and 33.4% in hippocampus and cortex, respectively was observed (Fig. 4c) through immunostaining with anti- $A\beta$ antibody upon oral delivery of CTB-MBP. Data shown is mean \pm S.D of values obtained from five adjacent sections from each mouse and evaluated from a total of 120 fluorescence images. Moreover, ThS staining showed up to 70% decrease in plaque number and 40% reduction in plaque intensity (Fig 4d) which was quite consistent in these age matched 3xTgAD mice across the group. These findings address the application of delivery of therapeutic protein, MBP; either through anticipated GM1 mediated receptor binding to the pentameric CTB of the fusion protein in the BBB or through compromised BBB in the AD model of transgenic mice allowing more BBB permeability for CTB-MBP delivery.



Number of stained plaques from Age matched 3xTg AD mice groups



% Reduction of ThS stained plaque intensity and number




Figure 4: Oral delivery of CTB-MBP chloroplast expressed protein decreased the amyloid plaque burden in a mouse model of AD.

Representative images (a, b) of the cortical and hippocampal amyloid plaque burden in 3xTg AD mice fed 3 times weekly over 12 weeks starting at 13-15 months of age with either recombinant CTB-MBP protein transgenic leaf extracts (31.2ug/300ul/day; n=10 mice, untransformed (WT) leaf extracts (300ul/day; n=4 mice), or unfed (n=4 mice). Sections were stained for amyloid plaques with either anti- A β antibody 2454 (red fluorescence; a) or Thioflavin S (green fluorescence; b) and with DAPI (blue) to label cell nuclei. Scale bar: hippocampus 100um (i) and 10um (ii) at different magnification, cortex 10um (iii)) (c) Quantification of the relative amounts of amyloid plaque load in the anti- A β stained sections from the animals treated with CTB-MBP and WT protein extracts as described in (a). (d) Quantification of the relative amounts of amyloid plaque number and intensity in the thioflavinS stained sections from the animals treated with CTB-MBP and WT protein extracts as described in (b). The mean plaque counts in the DG, CA1 and CA3 hippocampal and (mantle and pallium regions) cortical regions per section were determined with NIS Elements for Advanced Research. Data shown is mean \pm S.D of values obtained from five adjacent sections per mouse and five fields per section. Single factor ANOVA *p<0.05, **p<0.01, compared to mice treated with WT leaf extracts and unfed.

CHAPTER FOUR: DISCUSSION

This study shows efficient *in vivo* oral delivery of chloroplast expressed CTB-MBP fusion protein across BBB. The native confirmation of CTB pentamers facilitates binding to the intestinal GM1 receptors and effectively release the fused protein to the circulatory system when orally administered (35). CTB ensures the stability of fused protein through its pentameric confirmation. This work provides evidence for transport and efficient delivery of CTB fusion protein across BBB. Moreover, our findings support therapeutic MBP delivery into the brain *in vivo* potentially to reduce amyloid aggregates. Previous studies show presence of GM1 receptors on the BBB (36). The delivery of plant derived CTB-fusion protein can be anticipated to occur by GM1 receptor mediation through CTB-GM1 interaction on BBB, but additional experiments are required to address this mechanism. Moreover, BBB impairment is associated with more rapid progression in AD over 1 year (39). Clinical studies show that BBB is compromised in AD brains (40). With the damage of anatomical organization of BBB we anticipate increased BBB permeability, facilitating delivery of therapeutic proteins across BBB, further enhancing their delivery. Likewise, ability of bioencapsulated CTB-MBP to reduce amyloid levels *in vivo* indicates another path of efficient delivery of protein across disrupted BBB from site of administration, while maintaining its functional and structural integrity. This provides an inexpensive plant based application of delivering therapeutic protein across BBB.

Both widespread and diffused myelin breakdown (41) in the brains has been reported in patients with AD. Correlation of amyloid deposition with destruction of myelin also contributes the progression of age dependent AD (42). Myelin basic protein covers the myelin membranes and holds the lipid bilayer through electrostatic interactions in the CNS (43), ensuring its

importance in myelination and neurotransmission processes. Along with serine 151 residue serving as an active site for autocatalysis in MBP, its ability to interact with A β peptides, or degradation of fibril amyloid deposits have been previously discussed based on *in vitro* studies (15, 17, 18), consistent with our study and showing the capability of MBP to degrade A β .

This study also shows an optimal reduction up to 48% of thioflavin S stained amyloid deposits in advanced human AD post mortem brain sections, when incubated with chloroplast derived MBP. The significant reduction in human brains insights the functional degrading activity of plant expressed MBP *ex vivo*. Due to limited availability of human brain sections, anti-A β immunostaining could not be performed. Although in each brain section, obtained from different individual suffering with Alzheimer's disease at an advanced stage, consistent ThS staining reduction was noticed upon incubation. Moreover, with a higher purity of plant derived MBP, more effective degradation results could have been observed.

We observed a concentration-dependent degradation and/or reduction of amyloid levels of up to 66% in the brains of old 3xTg AD mice upon MBP incubation. Therefore, in this study, our investigations focus on the role of MBP to reduce the amyloid levels *in vivo* in 3xTg AD mice and *ex vivo* in brains of advanced AD individuals, by CTB mediated delivery of MBP that was expressed in plant cells through chloroplast engineering. We observed that 3xTg AD mice brain showed up to 67% and 33% decrease of amyloid levels when fed with CTB-MBP, particularly in dentate gyrus, CA1 and CA3 regions of hippocampal and in cortical brain regions, that are known to carry the most amyloid burden as a certain pathology in transgenic AD mice as well as in human AD (44). Immunostaining and thioflavin fluorescence, quantified and analyzed by fluorescence microscopy, were used to detect A β deposits. Moreover, thioflavin positive

amyloid deposits were observed in the areas of anti-amyloid immunoreactivity by staining hippocampus in adjacent brain sections in *in vivo* studies with anti-amyloid antibody and thioflavin S. This study quantitatively confirms the reduction of immunoreactive amyloid deposits in brain sections from oral delivery of CTB-MBP in old 3xTg AD mice. Histological analyses confirms quantitative as well as qualitative reduction of A β accumulation pathology through MBP in 3xTg AD mice and human AD.

Medical imaging techniques like magnetic resonance imaging (MRI) measure the structural integrity of myelin (45). Both widespread and diffused myelin breakdown (41, 46) in the brains has been reported in patients with AD. Correlation of amyloid deposition with destruction of myelin also contributes the progression of age dependent AD (42, 47). Studies report that slow myelin turnover rate could occur (48) because oligodendrocytes in the central nervous system (CNS) may differentiate in the brain development process with condensed myelin repair ability, thereby contributing to myelin degeneration.

Another hallmark of AD observed in 3xTgAD mice is neurofibrillary tangles that comprise of tau proteins (49) which are pathologic in their hyper-phosphorylated state and appears after A β deposition. It is possible that contribution of these tangles towards pathology may be reduced by MBP and hence demands further investigations for their reduction in brains of AD patients and transgenic mice model. In addition, the clearance of amyloid load in our investigation also warrants further behavioral studies in 3xTgAD mice over a long term period by oral delivery of bioencapsulated CTB-MBP. However, behavioral changes should be investigated in mice, fed with plant material simultaneously, at an early age of developing AD.

Recent findings suggest that A β accumulation is related to stress-induced senescence of astrocytes (50), by losing their ability for homeostasis maintenance in CNS. It remains to be determined from our findings if clearance of A β from brain would decrease astrocytes senescence, which contributes to pathogenesis and progression of AD (50). In addition, it has been suggested that zinc sequestration by A β deposits is susceptible to AD pathology (51), by inducing A β aggregation and disturbing zinc homeostasis. The therapeutic approach suggested by our investigations could also help elucidate mechanistic approaches for zinc distribution associated with pathology in AD.

Active and passive immunotherapies have been reported to target A β in clinical studies (11) through immunization, but recent disappointment with bapineuzumab antibody in clinical trial III calls for alternative strategy for Alzheimer's drugs and therapies. The 2011 world Alzheimer's report concludes that up to 28 million people with dementia, lack efficient diagnosis, treatment and care (52), increasing the "treatment gap" from high to low and middle income countries. Not only the need for novel strategies are needed but also the urge to halt it at an initial stage will be proven beneficial (53). Our lab used genetically engineered plants for expression and oral delivery of proinsulin (29), insulin and C peptide (30), exendin 4 (25) for treatment of diabetes or blood clotting factor IX for hemophilia B (31). Here we report expression of CTB fused with MBP in tobacco plant chloroplasts and their expression as a fusion protein. Lyophilization of leaf materials increases concentration of bioencapsulated transgenic protein for oral delivery. Lyophilization of plant cells increased CTB-MBP concentration, resulting in CTB-MBP capsules to be stored at room temperature for several months without any degradation of therapeutic protein. Oral delivery of therapeutic protein MBP, through GM1

receptor mediated delivery of CTB to the circulatory system and to the brain across the blood brain barrier in the AD model of transgenic mice in vivo and in advanced human AD brains ex vivo, opens the door for a novel concept and further advances in human clinical studies.

REFERENCES

- (1) A. Wimo and M. Prince, World Alzheimer Report 2010: The Global Economic Impact of Dementia, Alzheimer's Disease International, London, UK, 2010.
- (2) M. Prince, R. Bryce, C. Ferri, World Alzheimer Report 2011: The Benefits of early diagnosis and intervention, Alzheimer's Disease International, London, UK, 2011.
- (3) Mehta, M., Adem, A. & Sabbagh, M. New acetylcholinesterase inhibitors for Alzheimer's disease. *Int. J. of Alzheimer's Dis.* **2012**, (2012) 8 pages.
- (4) Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S. & Möbius, H.J. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med* **348**, 1333-1341 (2003).
- (5) Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297** (2002) 353-356.
- (6) Mawuenyega, K.G. *et al.* Decreased clearance of CNS β -amyloid in Alzheimer's disease. *Science* **330**, 1774 (2010).
- (7) Klunk, W. E. *et al.* Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B, *Ann Neurol* **55**, 306-319 (2004).

- (8) Jack, C. R. Jr. *et al.* Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease, *Brain* **132**, 1355-1365 (2009).
- (9) Tabaton, M. & Tamagno, E. The molecular link between beta- and gamma-secretase activity on the amyloid beta precursor protein. *Cell Mol Life Sci* **64**, 2211-2218 (2007).
- (10) Tsai, J., Grutzendler, J., Duff, K. & Gan, W. B. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. *Nat Neurosci* **7**, 1181-1183 (2004).
- (11) Fu, H.J., Liu, B., Frost, J.L. & Lemere, C. A. Amyloid- β immunotherapy for Alzheimer's disease. *CNS Neurol Disord Drug Targets* **9**, 197-206 (2010).
- (12) Lobello, K., Ryan, J. M., Liu, E., Rippon, G. & Black, R. Targeting beta amyloid: A clinical review of immunotherapeutic approaches in Alzheimer's disease. *Int. J. Alzheimers Dis.* **2012**, doi:10.1155/2012/628070 (2012).
- (13) Farlow, M. R. *et al.* Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. *Clin Ther* **32**,1234-51 (2010).

- (14) Jann, M. W., Shirley, K. L. & Smal, G. W. 2002. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. *Clin Pharmacokinet* **41**, 719-739 (2002).
- (15) Liao, M.C, Ahmed, M., Smith, S.O. & Van Nostrand, W.E. Degradation of amyloid- β protein by purified myelin basic protein, *J. Biol. Chem.* **284**, 28917-25 (2009).
- (16) Harauz, G., Ladizhansky, V. & Boggs, J. M. Structural polymorphism and multifunctionality of myelin basic protein, *Biochem.* **48**, 8094-8104 (2009).
- (17) Hoos, M. D., Ahmed, M., Smith, S. O. & Van Nostrand, W.E. Myelin basic protein binds to and inhibits the fibrillar assembly of Abeta42 in vitro. *Biochem* **48**, 4720-4727 (2009).
- (18) Liao, M.C. *et al.* N-terminal domain of myelin basic protein inhibits amyloid beta-protein fibril assembly. *J Biol Chem* **285**, 35590-35598 (2010).
- (19) Lippmann, E. S. *et al.* Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells. *Nat. Biotech.* **30**, 783-91 (2012).
- (20) Georgieva, J. V. *et al.* Peptide-Mediated Blood–Brain Barrier Transport of Polymersomes. *Angew. Chem. Int. Ed. Engl.* **51**, 8339-8342 (2012).

- (21) Stojanov, K *et al.* In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice. *Mol Pharm.* **9**, 1620-7 (2012).
- (22) Orlandi P. A. & Fishman, P. H. Filipin-dependent Inhibition of Cholera Toxin: Evidence for Toxin Internalization and Activation through Caveolae-like Domains *JCB* **141**, 905-915 (1998).
- (23) Alisky, J. M., van de Wetering, C. I. & Davidson, B. L. Widespread dispersal of cholera toxin subunit B to brain and spinal cord neurons following systemic delivery. *Exp Neurol* **178**, 139 (2002).
- (24) Zimran, A. *et al.* Pivotal trial with plant-cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. *Blood* **118**, 5767-5773 (2011).
- (25) Kwon, K.C., Nityanandam, R., New, J. S. & Daniell, H. Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. *Plant Biotechnol. J.* advance online publication 18 Oct 2012 (DOI: 10.1111/pbi.12008).

- (26) Ruhlman, T., Verma, D., Samson, N. & Daniell, H. The Role of Heterologous Chloroplast Sequence Elements in Transgene Integration and Expression. *Plant Physiology* **152**, 2088-2104 (2010).
- (27) Daniell, H. Transgene containment by maternal inheritance: effective or elusive? *Proc Natl Acad Sci USA* **104**, 6879-6880 (2007).
- (28) Daniell, H., Singh, N. D., Mason, H. & Streatfield, S. J. Plant-made vaccine antigens and biopharmaceuticals. *Trends Plant Sci* **14**, 669-679 (2009).
- (29) Ruhlman, T., Ahangari, R., Devine, A., Samsam, M. & Daniell, H. Expression of cholera toxin B–proinsulin fusion protein in lettuce and tobacco chloroplasts – oral administration protects against development of insulinitis in non-obese diabetic mice. *Plant Biotechnol J.* **5**, 495-510 (2007).
- (30) Boyhan, D., & Daniell, H. Low-cost production of proinsulin in tobacco and lettuce chloroplasts for injectable or oral delivery of functional insulin and C-peptide. *Plant Biotechnol J* **9**, 585-598 (2011).
- (31) Verma, D., *et al.* Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. *Proc Natl Acad Sci USA* **107**, 7101-7106 (2010).

- (32) Koya, V. *et al.* Plant-Based Vaccine: Mice Immunized with Chloroplast-Derived Anthrax Protective Antigen Survive Anthrax Lethal Toxin Challenge. *Infect. Immun.* **73**, 8266-8274 (2005).
- (33) Fernández-San Millán, A., *et al.* Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. *Plant Biotechnol J.* **6**, 427-441 (2008).
- (34) Davoodi-Semiromi, A., *et al.* Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. *Plant Biotechnol J.* **8**, 223-242 (2010).
- (35) Limaye, A., Koya, V., Samsam, M. & Daniell, H. Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic chloroplasts into the mouse circulatory system. *FASEB J* **20**, 959-61 (2006).
- (36) Georgieva, J.V. Peptide-mediated blood-brain barrier transport of polymersomes. *Angew. Chem. Int. Edit.* **51**, 8339-8342 (2012).
- (37) Verma, D., Samson, N. P., Koya, V. & Daniell, H. A protocol for expression of foreign genes in chloroplasts. *Nat Protoc* **3**, 739-58 (2008).

- (38) Chigurupati, S. *et al.* Evidence for altered numb isoform levels in Alzheimer Disease patients and a triple transgenic mouse model. *J Alzheimers Dis.* **24**, 349-361 (2011).
- (39) Bowman G. L. *et al.* Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. *Neurology* **68**, 1809-1814 (2007).
- (40) Bowman, G. L., Kaye, J. A. & Quinn, J. F. Dyslipidemia and blood-brain barrier integrity in Alzheimer's disease. *Curr Gerontol Geriatr Res* 2012, 184042 (2012).
- (41) Brun, A. & Englund, E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. *Ann Neurol.* **19**, 253-262 (1986).
- (42) Torp, R. *et al.* Ultrastructural evidence of fibrillar β -amyloid associated with neuronal membranes in behaviorally characterized aged dog brains. *Neuroscience.* **96**:495-506 (2000).
- (43) Boggs, J. M. Myelin basic protein: a multifunctional protein. *Cell Mol Life Sci* **63**, 1945-1961 (2006).
- (44) Reilly, J. F. *et al.* Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. *Proc Natl Acad Sci U S A.* **15**, 4837-4842 (2003).

- (45) Bartzokis, G. *et al.* White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. *Archives of neurology*. **60**, 393-398 (2003).
- (46) Erkinjuntti, T. *et al.* Diffuse vacuolization (spongiosis) and arteriolosclerosis in the frontal white matter occurs in vascular dementia. *Arch Neurol*. **53**, 325- 332 (1996).
- (47) Kiuru, S., Salonen, O. & Haltia, M. Gelsolin-related spinal and cerebral amyloid angiopathy. *Ann Neurol*. **45**, 305-311 (1999).
- (48) Hildebrand, C., Remahl, S., Persson, H. & Bjartmar, C. Myelinated nerve fibres in the CNS. *Prog Neurobiol*. **40**, 319- 384 (1993).
- (49) Oddo, S. *et al.* Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A β and synaptic dysfunction. *Neuron* **39**, 409-421 (2003).
- (50) Bhatt, R. *et al.* Astrocyte senescence as a component of Alzheimer's disease. *PLoS One* **7**, e45069 (2012).
- (51) Craddock, T.J.A. *et al.* The zinc dyshomeostasis hypothesis of Alzheimer's disease. *PLoS One* **7**, e33552 (2012).

(52) Prince, M., Bryce, R. & Ferri, C. World Alzheimer Report 2011: The Benefits of early diagnosis and intervention. Alzheimer's Disease International, London, UK (2011).

(53) Miller, G. Stopping Alzheimer's before it starts. *Science* **337**, 790-792 (2012).